HCW Biologics says TGF-β trap-IL-15 fusion expands CD8+ T, NK cells in human studies

• HCW Biologics highlighted human data showing its TGF-β trap–IL-15 fusion expanded progenitor CD8+ T cells and NK cells.
• Program reported clinical benefit in cancer patients, with the fusion described as well tolerated.
• Preclinical work showed activity in models of HIV-1 and bronchopulmonary dysplasia.
• Second-generation pipeline now embeds the TGF-β/IL-15 moiety into TRBC-based TCE and ICI constructs.
• Lead candidates HCW11-018b and HCW11-040 are IND-enabling, with first clinical studies planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250900PRIMZONEFULLFEED9815252) on August 25, 2026, and is solely responsible for the information contained therein.